Tenderwize
Retour à la recherche

Open house drug rebate agreements Lanthanum(III)-carbonate, ATC V03AE03

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 03, 2028 · 613 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lanthan(III)-carbonat, ATC V03AE03

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or guaranteed volume; revenue depends on actual usage and discount rates

Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Non-exclusive pharmaceutical rebate agreements for Lanthanum(III)-carbonate (ATC V03AE03)
  • Supply of pharmaceutical products to AOK Bayern at discounted prices
Afficher le résumé complet

Non-exclusive open-house model for pharmaceutical rebate agreements on Lanthanum(III) carbonate (ATC V03AE03) with AOK Bayern. Eligible pharmaceutical companies can join at any time until 03 May 2028, with contracts running from 01 July 2026 to 30 June 2028. No estimated value provided. Submission is either in writing (two copies) or electronically with qualified electronic signature. Only self-declaration of reliability is required for eligibility. The contract is non-negotiable and non-exclusive.

Risques

No estimated value or guaranteed volume; revenue depends on actual usage and discount rates

Automatic termination if a competing nationwide or state-level rebate contract is concluded for the same active substan...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible

Administrative

  • Submission of signed self-declaration of reliability
  • Submission of signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – all eligible companies are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug rebate agreements Lanthanum(III)-carbonate, ATC V03AE03

Open-house model for non-exclusive rebate agreements on pharmaceutical products containing Lanthanum(III)-carbonate (ATC V03AE03). Contracts available to all interested pharmaceutical companies meeting eligibility criteria. No selection process; all eligible companies can join. Duration from 01 July 2026 to 30 June 2028. Submission deadlines for joining: 3rd of each month for next month start, or later. Contracts may be terminated with one month's notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jun 2026 - Jun 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – all eligible companies are accepted.

Date limite

Deadline May 03, 2028

Détails de la procédure

Date de publication
17 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
337536-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30